Huntsville, AL – Eli Lilly and Company today announced plans to construct a $6 billion pharmaceutical manufacturing campus near Madison, Alabama. This initiative represents the largest private industrial investment in the state’s history and is expected to significantly enhance domestic production of next-generation medicines.
The new facility will be located on a 260-acre site near Interstate 565 and Greenbrier Parkway and will focus on the production of advanced active pharmaceutical ingredients for treatments in areas such as diabetes, cancer, and obesity. Construction is scheduled to begin in 2026, with operations gradually scaling up through 2032.
The project is expected to generate 450 full-time positions across engineering, research, technical operations, and quality control, along with approximately 3,000 construction jobs during the building phase.
Local and State Leadership Comments
“Huntsville’s selection by Eli Lilly highlights our region’s expertise in science, innovation, and advanced manufacturing,” said Huntsville Mayor Tommy Battle.
Governor Kay Ivey noted, “This investment strengthens Alabama’s legacy in bioscience and advanced manufacturing and will have a lasting positive impact on our communities.”
Strategic and Technological Highlights
Eli Lilly CEO David A. Ricks emphasized that Huntsville was chosen for its skilled workforce, scientific infrastructure, and manufacturing readiness. The campus will feature advanced automation, AI-driven manufacturing systems, and integrated digital monitoring, positioning the site as a key hub for domestic medicine production and supply chain resilience.
The city of Madison stated: “This transformational project is set to be the largest economic investment in Alabama’s history, with an estimated $25 billion impact on our local economy. It underscores our region’s role in advancing innovation, creating jobs, and supporting global health.”
About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical leader committed to discovering and delivering innovative medicines that improve patient outcomes. The company focuses on areas including diabetes, oncology, neuroscience, immunology, and cardiovascular health.
For more information, visit www.lilly.com.
By